$74B – Health

BREAKING: Thumbs-up on $74B BMS-Celgene deal ends months of activist outrage

Bristol-Myers Squibb CEO Giovanni Caforio was less than 10 minutes into a special shareholders meeting on the company’s proposed $ 74 billion acquisition of Celgene when a broker interrupted his attempt to wrap up voting on the deal. “Are you going to address the dissenting votes?” he asked. “My family has owned tremendous quantities of… Read More »

JPM 2019: Bristol-Myers, Celgene CEOs trot out detailed case for $74B megadeal

SAN FRANCISCO—Bristol-Myers Squibb and Celgene sent 2019’s first big shockwave throughout pharma with last week’s $ 74 billion megamerger announcement. And they immediately touched off questions about the deal: Analysts called it too expensive, not to mention risky on the patent side and pipeline, too. But even as market watchers continued to offer up their reservations on… Read More »